Quanterix(QTRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $43.9 million, a 25% increase year-over-year and a 7% increase sequentially [11] - Organic revenue declined by 22% [11] - Adjusted EBITDA was a loss of $7.9 million, an improvement from a loss of $11.9 million in Q3 [16] - The company ended the quarter with $122 million in cash equivalents and marketable securities [16] Business Line Data and Key Metrics Changes - Revenue from diagnostics partners was $3.1 million in the quarter [11] - Simoa contributed $27 million, reflecting a 22% organic revenue decline [11] - Spatial reported $17 million, down 23% year-over-year, with a 16% decline when excluding a terminated diagnostics development agreement [11] - Instrument revenue was $6.1 million, with 21 Simoa and 17 Spatial instruments placed in the quarter [12] Market Data and Key Metrics Changes - Academic customers represented approximately 55% of the business in Q4 [12] - Pharma revenue declined by 21% year-over-year due to lower large Accelerator projects [13] - The company has 25 partnerships generating $9.6 million in revenue during 2025, up from $6 million in the prior year [13] Company Strategy and Development Direction - The company aims to achieve break-even profitability in 2026, with a focus on operational rigor and steady growth [8][16] - The LucentAD Complete test for Alzheimer's disease has received a reimbursement rate approval of $897, which is expected to enhance market penetration [14] - The company plans to launch additional products in the tau biomarker field, indicating a commitment to innovation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's base business and the plan for break-even profitability [19] - The CEO emphasized the importance of understanding customer needs and strategic partnerships to drive growth [9] - The company anticipates a minimal impact on core business from the terminated diagnostics agreement, with pro forma revenue expected to increase by approximately 2% in 2026 [18] Other Important Information - The company has implemented $74 million of its $85 million cost synergy target and is on track to meet this by the end of Q1 [16] - The company launched 13 new assays in 2025 and plans for a continuous stream of assay launches throughout 2026 [27] Q&A Session Summary Question: Assessment of Quanterix's core high sensitivity proteomics and Spatial Biology businesses - The CEO noted effective execution in diversifying the business and achieving synergy targets, with a focus on growth in both Simoa and Akoya spatial spaces [23][24] Question: New assay or product launches planned for 2026 - The CFO confirmed a regular cadence of assay launches is expected, with several already in the pipeline for Q1 [27] Question: Prioritization of diagnostics versus Simoa proteomics and Spatial business - The CEO highlighted the importance of the Alzheimer's diagnostics opportunity and ongoing clinical utility studies to guide payer engagement [34] Question: Update on FDA submission and potential timeline for product approval - The CEO mentioned that the FDA approval for the 510(k) submission is expected within 6 to 9 months, aiming for Q4 approval [38]